Whalesbook
Anthem Biosciences reported a strong operational performance in Q4 FY26, highlighted by a 37% year-over-year increase in EBITDA. This growth was primarily driven by its Contract Research, Development, and Manufacturing Organization (CRDMO) segment and the increasing success of its commercial product offerings. The company's strategic investments in expanding manufacturing capacity, especially for high-demand molecules like those used in GLP-1 treatments, are expected to support its future growth.
Growth Drivers: CRDMO and Specialty Ingredients
The CRDMO business remains Anthem Biosciences' main revenue source, accounting for about 83% of total revenue in FY26 and growing 18% year-over-year. This sustained growth reflects strong demand for its comprehensive drug discovery, development, and manufacturing services. The specialty ingredients segment also shows potential, with plans to scale up Active Pharmaceutical Ingredient (API) production for GLP-1 drugs in the second half of 2026. This two-pronged strategy allows Anthem Biosciences to target both established and emerging market opportunities.
Valuation vs. Analyst Confidence
Despite impressive financial results, Anthem Biosciences' valuation is a significant topic. The company currently trades at a Price-to-Earnings (P/E) multiple of roughly 72x and an Enterprise Value to EBITDA (EV/EBITDA) of about 50x, well above the pharmaceutical industry average of 35x. This premium valuation has led to mixed analyst views. While some reports suggest a 'SELL' rating due to high multiples, prominent analysts at Prabhudas Lilladher maintain a 'BUY' recommendation with a revised target price of INR 850. They cite strong growth prospects and upcoming capacity expansions as positive catalysts, indicating an ongoing market debate on the company's worth versus its operational performance.
Strategic Expansion and Financial Strength
Anthem Biosciences plans to invest INR 10-12 billion over the next two years, funded mainly through its own earnings, to expand manufacturing capabilities. Key projects include Unit 4, which aims to double custom synthesis capacity and increase fermentation capacity by 50% by March 2028. The company's financial health is strong, with a net cash position of INR 1,375 crore as of March 31, 2026, and a low debt-to-EBITDA ratio of 0.16. This solid financial base will support its growth initiatives.
Challenges: High Valuation and Competition
The primary challenge for Anthem Biosciences is its high valuation multiples, with P/E ratios reaching up to 91.6x and Price to Book at 15.30x. This premium valuation leaves little room for disappointment if growth targets are missed or market challenges emerge. The company also faces intense competition in peptide manufacturing and CRDMO services from domestic and international players. Although Anthem Biosciences holds an advantage as a backward-integrated peptide manufacturer, offering cost benefits over Chinese competitors for products like GLP-1, ongoing competition could impact its margins and market share. The exact timing of commercialization for key products, such as GLP-1, also poses a risk to short-term revenue forecasts.
Future Outlook and Analyst Consensus
Prabhudas Lilladher forecasts revenue and EBITDA to grow at a Compound Annual Growth Rate (CAGR) of around 21% and 22% respectively between FY26 and FY28. This growth is expected to be driven by CDMO services (23%), CRO services (11%), and specialty ingredients (14%). Anthem Biosciences' focus on high-growth areas like GLP-1 and peptides, combined with capacity expansions and a strong balance sheet, positions it for continued growth. A consensus 'BUY' rating from 7 analysts with an average price target of INR 786.86 suggests a positive outlook, despite the current premium valuation.